HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Havel, M. P. Articles by Wolner, E. Search for Related Content PubMed PubMed Citation Articles by Havel, M. P. Articles by Wolner, E.

The Journal of Thoracic and Cardiovascular Surgery, Vol 104, 654-658, Copyright © 1992 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Aprotinin decreases release of 6-keto-prostaglandin F1 alpha and increases release of thromboxane B2 in cultured human umbilical vein endothelial cells

MP Havel, A Griesmacher, G Weigel, A Owen, P Simon, MM Muller and E Wolner
Second Surgical Clinic, University of Vienna, Austria.

Use of the proteinase inhibitor aprotinin significantly improves hemostasis and reduces bleeding after operations in which extracorporeal circulation is used. The mechanism of action, however, has been only partially clarified. In this work we investigated whether aprotinin influenced the production and release of the eicosanoids prostacyclin, measured as the stable metabolite 6-keto-prostaglandin F1 alpha, and thromboxane A2, measured as the stable metabolite thromboxane B2, from endothelial cells. Human umbilical vein endothelial cells were incubated with different concentrations of aprotinin (5.5, 20, 55, and 100 mumol/L). The levels of 6-keto- prostaglandin F1 alpha and thromboxane B2 were measured at baseline and after thrombin stimulation. A concentration-dependent effect of aprotinin on 6-keto-prostaglandin F1 alpha synthesis was demonstrated. After incubation with 100 mumol/L of aprotinin, a 90% reduction in 6- keto-prostaglandin F1 alpha production was seen (31.69 versus 307.44 picograms per million cells; p less than 0.001). Conversely, thromboxane B2 production showed a 345% increase after incubation with aprotinin (287.80 versus 83.82 picograms per million cells; p less than 0.0001). Since 6-keto-prostaglandin F1 alpha inhibits and thromboxane B2 strongly enhances platelet aggregation, it appears that one mechanism of the clinically observed effectiveness of aprotinin lies in the altered ratio of 6-keto-prostaglandin F1 alpha: thromboxane B2 in endothelial cells, which leads to enhanced platelet aggregation and improved vessel sealing.

This article has been cited by other articles:

				D. T. Mangano, Y. Miao, A. Vuylsteke, I. C. Tudor, R. Juneja, D. Filipescu, A. Hoeft, M. L. Fontes, Z. Hillel, E. Ott, et al. Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery JAMA, February 7, 2007; 297(5): 471 - 479. [Abstract] [Full Text] [PDF]

				S. C. Body and C. D. Mazer Pro: Aprotinin Has a Good Efficacy and Safety Profile Relative to Other Alternatives for Prevention of Bleeding in Cardiac Surgery Anesth. Analg., December 1, 2006; 103(6): 1354 - 1359. [Full Text] [PDF]

				D. T. Mangano, I. C. Tudor, C. Dietzel, and the Multicenter Study of Perioperative Ischemia Re The Risk Associated with Aprotinin in Cardiac Surgery N. Engl. J. Med., January 26, 2006; 354(4): 353 - 365. [Abstract] [Full Text] [PDF]

				S. Ulker, P. P McKeown, and U. Bayraktutan Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells Cardiovasc Res, September 1, 2002; 55(4): 830 - 837. [Abstract] [Full Text] [PDF]

				S. Ulker, M. G. Cinar, U. Bayraktutan, and A. Evinc Aprotinin impairs endothelium-dependent relaxation in rat aorta and inhibits nitric oxide release from rat coronary endothelial cells Cardiovasc Res, June 1, 2001; 50(3): 589 - 596. [Abstract] [Full Text] [PDF]

				S. Westaby Aprotinin Fifteen Years Later Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 366 - 375. [Abstract] [PDF]

				D. Royston Hemostatic Drugs in Prothrombotic or Hypercoagulable States Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 376 - 394. [Abstract] [PDF]

				E. A. Bukhari, I. B. Krukenkamp, P. G. Burns, G. R. Gaudette, J. J. Schulman, M. R. Al-Fagih, and S. Levitsky Does Aprotinin Increase the Myocardial Damage in the Setting of Ischemia and Preconditioning? Ann. Thorac. Surg., August 1, 1995; 60(2): 307 - 310. [Abstract] [Full Text]

				D. J. Goldstein, J. A. Seldomridge, J. M. Chen, K. A. Catanese, C. M. DeRosa, A. D. Weinberg, C. R. Smith, E. A. Rose, H. R. Levin, and M. C. Oz Use of Aprotinin in LVAD Recipients Reduces Blood Loss, Blood Use, and Perioperative Mortality Ann. Thorac. Surg., May 1, 1995; 59(5): 1063 - 1067. [Abstract] [Full Text]

				G. J. Despotis, J. H. Joist, D. Joiner-Maier, A. L. Alsoufiev, A. N. Triantafillou, L. T. Goodnough, S. A. Santoro, and D. G. Lappas Effect of Aprotinin on Activated Clotting Time, Whole Blood and Plasma Heparin Measurements Ann. Thorac. Surg., January 1, 1995; 59(1): 106 - 111. [Abstract] [Full Text]

				M. Havel, F. Grabenwoger, J. Schneider, G. Laufer, G. Wollenek, A. Owen, P. Simon, H. Teufelsbauer, and E. Wolner Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood J. Thorac. Cardiovasc. Surg., March 1, 1994; 107(3): 807 - 810. [Abstract] [Full Text]